title: Pharmacokinetic profile of recombinant human (rh) inhibin A and activin A in the immature rat. I. Serum profile of rh-inhibin A and rh-activin A in the immature female rat.
abstract: The serum pharmacokinetics of recombinant human inhibin A (rh-inhibin A) and rh-activin A were examined in immature female Sprague Dawley-derived rats after iv and sc injection of the drugs. After iv administration of rh-inhibin A (120 micrograms/kg), the serum concentrations were described by a biexponential equation. The weight-normalized clearance was 21.3 ml/min.kg, and the initial (t1/2 alpha) and terminal (t1/2 beta) half-lives were 2.9 min and 37.9 min, respectively. Subcutaneous administration of 120 micrograms/kg rh-inhibin A resulted in a peak serum concentration of 10.6 ng/ml at 30.8 min after injection. Approximately 24% of the sc administered material was absorbed. Serum concentrations of rh-activin A also declined biexponentially after iv injection of the drug (120 micrograms/kg). The clearance of rh-activin A was 5.1 ml/min.kg, the t1/2 alpha was 6.1 min, and the t1/2 beta was 46.3 min. The peak serum concentration of rh-activin A (104.7 ng/ml) was achieved 24.7 min after sc delivery of the drug. The bioavailability of the sc dose was 38%. Iodinated rh-inhibin A and rh-activin A were used to examine the serum forms and metabolites of the drugs. [125I]rh-inhibin A and [125I]rh-activin A associated with two serum-binding proteins. Within 2 min of iv injection, the labeled hormones bound follistatin and alpha-2-macroglobulin. Even though rh-inhibin A and rh-activin A are structurally similar and appear to bind to the same serum proteins, their disposition in the immature rat differ.
authors.affiliation: Department of Cell Culture and Fermentation Research and Development, Genentech, Inc., South San Francisco, California 94080.
authors.forename: T K
authors.initials: TK
authors.lastname: Woodruff
authors.forename: L A
authors.initials: LA
authors.lastname: Krummen
authors.forename: S
authors.initials: S
authors.lastname: Chen
authors.forename: G
authors.initials: G
authors.lastname: DeGuzman
authors.forename: R
authors.initials: R
authors.lastname: Lyon
authors.forename: D L
authors.initials: DL
authors.lastname: Baly
authors.forename: D E
authors.initials: DE
authors.lastname: Allison
authors.forename: S
authors.initials: S
authors.lastname: Garg
authors.forename: W L
authors.initials: WL
authors.lastname: Wong
authors.forename: N
authors.initials: N
authors.lastname: Hebert
mesh_terms: D028341:Activins; D000375:Aging / Q000378:metabolism; D000818:Animals; D001798:Blood Proteins / Q000378:metabolism; D015153:Blotting, Western; D002851:Chromatography, High Pressure Liquid; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006133:Growth Substances / Q000493:pharmacokinetics*; D006801:Humans; D007265:Inhibins / Q000097:blood / Q000493:pharmacokinetics*; D008657:Metabolic Clearance Rate; D011485:Protein Binding; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000493:pharmacokinetics; D014018:Tissue Distribution
chemical_list: D001798:Blood Proteins; D006133:Growth Substances; D011994:Recombinant Proteins; D028341:Activins; D007265:Inhibins